secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2023-03-22T23:59:59+00:00
Accession:  0001683168-23-001679
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals reports 2022 net loss of $11.5M and provides pipeline updates
--------------------------------------------------------------------------------

- Cash at Dec 31, 2022: $11.8M, down from $24.1M a year earlier; funds operations through Q4 2023.
- Net loss of $11.5M ($10.10/share) vs $13.3M ($12.43/share) in 2021; R&D expenses fell 21% to $7.0M.
- DMC recommended proceeding to second cohort of PH-762 Phase 1b for advanced melanoma after no safety issues.
- FDA cleared partner AgonOx to start Phase 1 ACT trial with PH-762 for solid tumors; PH-894 IND-enabling studies complete.
- Robert Bitterman appointed President and CEO (previously interim CEO); Nasdaq compliance regained after reverse split.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/0001683168-23-001679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316823001679/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-001679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer